Table of Contents

PART 1 – The Patient Journey

Foreword 01

Author list 03

Introduction 12

If ADHD has been diagnosed, when should ADHD medications be considered? 12

Who should prescribe ADHD medications? 13

What are the important issues to consider when a decision has been made to start pharmacological treatment for ADHD? 14

Understanding the pharmacokinetics and pharmacodynamics of the medications used to treat ADHD 14

Psychoeducation and consent 14

What additional assessments should be conducted prior to starting medication? 15

BOX 1: Cardiac Risk Assessment 16

Off-label prescribing 17

BOX 2: Principles when considering an off-label trial of psychotropic medication for children and adolescents 18

Medication choice 20

Which should be the first medication for ADHD? 20

Why one stimulant would be used over another? 20

What are the key differences between dexamfetamine and methylphenidate? 20

Why is it necessary to understand the pharmacokinetic and pharmacodynamic profiles of the stimulants? 21

How do you switch between different methylphenidate preparations? 21

Clinical Practice Points for extended-release methylphenidate preparations: 22

TABLE 1: Dose equivalence chart for switching between methylphenidate preparations 23

How do you switch between dexamfetamine and lisdexamfetamine? 24

Clinical Practice Points for lisdexamfetamine 24

What are the best medication choices for children aged under 5 years? 24

What are the best medication choices for children and adolescents (aged 5 to 17 years) and adults (aged 18 years and above)? 25

Do the recommendations differ for adults over the age of 65 years? 26

What are the contraindications to using stimulant medications across the lifespan? 26

Medication choices for those with coexisting mental health conditions 26

Psychosis 27

Anxiety, mood disorders, tic disorder and autism spectrum disorder 27

Medication choices for those with coexisting substance use disorder 27

When should a non-stimulant medication be considered as a first choice for children and adolescents with ADHD? 28

When should a non-stimulant medication be considered as a first choice for adults with ADHD? 28

Titration and optimising dose 29

What is meant by optimising ADHD core symptoms and what are the best approaches to optimisation? 29

TABLE 2: Interpreting core symptom outcomes using standardised DSM-based rating scales (e.g., ADHD-RS-5, SNAP-IV or Vanderbilt score).* 31

Are there situations when the approach to titration should be adjusted? 32

Titration Protocols- Stimulants 32

Should you start with a short acting or long-acting stimulant? 32

How fast should you titrate onto stimulants? 32

What are the maximum doses of the stimulants? 33

Examples of stimulant titration protocols used by the authors 34

Titration protocol - atomoxetine 34

Titration protocols - extended release guanfacine 35

Titration protocols - clonidine 36

What should I do if the first medication is not effective or tolerated? 36

If the first medication has been a stimulant and is not effective 37

If the first medication is poorly tolerated due to adverse effects 37

If the first medication has been a non-stimulant and is ineffective or not tolerated 38

If both stimulant classes have been tried at adequate doses and have either not been effective or not tolerated 38

Monitoring progress 40

How often should progress be monitored? 41

What should be included in a medication review appointment? 41

What rating scales are recommended for monitoring core ADHD symptoms? 41

Outcome measures for children and adolescents: 41

TABLE 2: Interpreting core symptom outcomes using standardised DSM-based rating scales (e.g., ADHD-RS-5, SNAP-IV or Vanderbilt score).* 43

Outcome measures for adults: 43

What are the best ways to monitor adverse effects? 43

TABLE 3: Monitoring other symptoms/adverse effects 44

The AADPA ADHDTracker App - a useful online tool for monitoring progress 45

Optimising long-term outcomes: what does the research say and why does it matter? 45

How long should you treat ADHD and how do you know when to stop medication? 46

Are there specific recommendations for stopping the different ADHD medications? 46

What approaches can help to maximise adherence to treatment? 47

How can we best engage children and young people in their treatment? 47

Should you use medication holidays? 48

What are the important things to consider before switching medications? 48

BOX 3: Questions to consider before switching medications or adding an additional medication **49**

If I am going to switch medication class, what order should I proceed in? 49

How do I tell if someone is becoming tolerant to their medication and if they are, what should I do? 50

Managing adverse effects **52**

What are the best practical approaches to aid in weight maintenance and growth 52

How do you monitor cardiovascular safety? 53

Other adverse effects 53

TABLE 4. Summary of recommendations updated from the European ADHD Guidelines Group review of the management of best practice in the management of adverse events during treatment with ADHD (Cortese et al 2013)(56) **55**

References **58**

Appendix 01: SUMMARY TABLE for ADHD medications **62**

Appendix 02: Medical and psychiatric precautions or contraindications for ADHD medications
Author Katarzyna (Kate) Tognarini **66**

Appendix 03: ADHD Medication use in Pregnancy and Breastfeeding
Author Katarzyna (Kate) Tognarini **70**

Appendix 04: Medication interactions, metabolism & elimination, side effects
Author Katarzyna (Kate) Tognarini **74**

Appendix 05: Sample titration protocols **80**

Dr Alison (Sally) Poulton - Paediatrician 80

David Coghill (child and youth psychiatrist) – titration onto methylphenidate, dexamfetamine, and lisdexamfetamine 83

Roger Paterson (child & adolescent and adult psychiatrist) 85

Roger Paterson - Medication Dose Schedule Guideline – Methylphenidate - Children 87

Roger Paterson - Medication Dose Schedule Guideline Dexamfetamine - Children 88

Roger Paterson - Medication Dose Schedule Guideline – Methylphenidate - Teens and Adults 89

Roger Paterson - Medication Dose Schedule Guideline – Dexamfetamine and Lisdexamfetamine - Teens and Adults 90

PART 2 – Frequently Asked Questions

1. When would you use the 'further medication choices' listed in the Guideline? 93

2. Acidifying/Alkalinizing Agents – what is the interaction between these and stimulant medications? 94

Interactions with Acidifying/Alkalinizing Agents 94

3. End of Dose Behaviour/Mood Changes – what can help? 95

4. What are the Pharmaceutical Benefits Scheme (PBS) Listings for ADHD Medications? 96

5. Which ADHD Medications contain Gluten and Lactose? 97

6. Can Lisdexamfetamine (Vyvanse) be Dissolved and Diluted and if so, what is the Stability? 98

7. How Can Pharmacists Help To Support People who are Using ADHD Medications? 99

Counselling on Specific Medication Types, Expected Effects, Side Effects, and Interactions 100

Information on Combining Medications with Caffeine, Alcohol or Cold and Flu Medications 101

8. Other Considerations (Special Populations - Comorbidities) 102

Comorbidities: How should Clinicians Approach Prescribing Stimulants to Patients with Other Conditions? 102

General comments on prescribing in the presence of other conditions from the Australian ADHD Evidence-Based Guideline Development Group: 102

Comorbidities: Does a clinician have to be wary or make any changes to practice when prescribing ADHD medications, to patients with a history of: 103

Anxiety 103

Depression 105

Tic Disorders (Tourette's Disorder) 106

Autism Spectrum Disorder (ASD) 108

Epilepsy 110

Psychosis/Schizophrenia/Drug-Induced Psychosis 112

Bipolar Disorder 115

Oppositional Defiant Disorder (ODD) 116

What are the recommendations for ADHD medications in the presence of Disordered Eating 118

Restless Legs Syndrome (RLS) 120

Skin Picking Behaviours and ADHD 122

9. Is there an association between Substance Use Disorder and ADHD and what are the recommendations? 123

10. Are there recommendations for Cannabis Use and Access to Medication? 125

11. Is there an association between Gambling Disorder (GD) and ADHD and what are the recommendations for treatment? 126

12. Are there specific issues for using ADHD medications in females: in general; during pregnancy; and while breastfeeding? 127

General Issues 127

Gender-Specific Issues in Diagnosis and Prescribing for Females 127

Hormonal Influences on Cognition and Mood 127

Comorbidities and Hormonal Fluctuations 128

The Role of Iron Status 128

Managing ADHD in Times of Hormonal Fluctuations 128

Medication Use in Pregnancy and Lactation 130

13. What are the Sleep Considerations for people with ADHD? 132

Does taking Melatonin Stop the Brain from Producing Its Own Melatonin? 133

14. Are Supplements, Nutraceuticals, and Phytoceuticals recommended in managing ADHD? 134

15. Driving and Roadside Tests: When it comes to driving and the use of stimulant medications for ADHD, what are the implications to consider? 137

16. Is there any data on the Long-Term Safety of Stimulant Medications? 139

17. What are the considerations for Domestic and International Travel? 141

18. Are there any considerations for the Criminal Justice System? 142

19. What are the Considerations with Sport? 143

20. What are the Career and Occupational Considerations? 144

21. Are there any recommendations for Pharmacogenetic Testing? 145

23. Are there particular issues regarding treatment of ADHD in Aboriginal and Torres Strait Islander Peoples? 146